Latest Candel Therapeutics News & Updates

See the latest news and media coverage for Candel. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Candel Therapeutics (Candel)

Clinical-stage biotech developing viral immunotherapy platforms for solid tumors

candeltx.com
Headquarters
Needham, United States
Founded year
1999
Company type
Public company
Number of employees
100–200
Industry
Pharmaceuticals

Last updated

Latest news about Candel Therapeutics (Candel)

In short: Candel initiated a global Phase 3 NSCLC trial, reported survival data, and advanced its prostate cancer BLA toward a Q4 2026 submission.

Company announcements

Candel

Candel advances its prostate cancer immunotherapy development pipeline

The company reports that phase 3 trials demonstrated meaningful improvements in disease-free survival for patients receiving the viral therapy alongside radiotherapy.

Unlock all announcements with a

Media coverage

Newsquawk

US BROKER MOVES: CIEN upgraded at Evercore; INVH & AMH upgraded at Mizuho | Newsquawk

Candel Therapeutics (CADL) upgraded from Neutral to Buy at BofA Securities; PT USD 18.00 (prev.

Unlock all articles with a

Never miss news about Candel

Track Candel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Candel competitors & trending companies

Browse news for competitors to Candel and other trending companies.